Liquidia (NASDAQ:LQDA) Sets New 12-Month High – Should You Buy?

Liquidia Corporation (NASDAQ:LQDA)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $41.57 and last traded at $38.79, with a volume of 2374182 shares trading hands. The stock had previously closed at $39.99.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Unusually large call-option activity: investors bought roughly 54,585 call options on Friday (about +375% vs. average call volume), which can indicate bullish bets or hedging by traders expecting upside in the near term.
• Positive Sentiment: Zacks upgraded LQDA from “hold” to “strong-buy,” a catalyst that can attract momentum-oriented investors and buy-side interest. Read More.
• Neutral Sentiment: Laughing Water Capital mentioned Liquidia in its Q4 2025 investor letter; the hedge fund reported modest positive returns for the quarter and year but the update does not directly signal a change in corporate fundamentals. Read More.
• Neutral Sentiment: Liquidia presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available); investor takeaways depend on specifics from the presentation (pipeline, commercial progress, guidance). Presentation transcripts tend to be informational until new data or guidance is revealed. Read More.
• Negative Sentiment: Multiple sizable insider sales were reported today across several filings — these include trades totaling roughly $507k, $768k, $493k and $791k (individual links below). Large, clustered insider selling can create near-term selling pressure and raise investor concern about insiders reducing exposure. Read More. Read More. Read More. Read More.
• Negative Sentiment: Additional insider transactions: the CAO sold shares worth ~$413k. Separate filing: director/executive Roger Jeffs sold 66,610 shares — both filings can be perceived negatively by the market. Read More. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LQDA. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of Liquidia in a research note on Friday, January 9th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. Wells Fargo & Company began coverage on shares of Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target for the company. Finally, Needham & Company LLC boosted their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.67.

Liquidia Price Performance

The firm has a 50-day simple moving average of $32.91 and a two-hundred day simple moving average of $26.04. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -26.34, a P/E/G ratio of 0.64 and a beta of 0.48. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. The firm had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company’s revenue was up 1106.7% compared to the same quarter last year. As a group, analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In related news, insider Jason Adair sold 35,656 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68. Following the sale, the insider owned 174,998 shares in the company, valued at approximately $5,255,189.94. This trade represents a 16.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Roger Jeffs sold 66,610 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the completion of the transaction, the chief executive officer owned 1,037,528 shares of the company’s stock, valued at approximately $38,834,673.04. This trade represents a 6.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 323,354 shares of company stock worth $11,046,731. Insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

Several institutional investors have recently bought and sold shares of LQDA. NewEdge Advisors LLC acquired a new stake in Liquidia in the second quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the 3rd quarter valued at $34,000. Steward Partners Investment Advisory LLC increased its holdings in Liquidia by 24.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).